168 related articles for article (PubMed ID: 18036248)
1. Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.
Motokura T; Nakamura Y; Sato H
BMC Cancer; 2007 Nov; 7():217. PubMed ID: 18036248
[TBL] [Abstract][Full Text] [Related]
2. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.
Mhawech P; Benz A; Cerato C; Greloz V; Assaly M; Desmond JC; Koeffler HP; Lodygin D; Hermeking H; Herrmann F; Schwaller J
Mod Pathol; 2005 Mar; 18(3):340-8. PubMed ID: 15257317
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
Schultz J; Ibrahim SM; Vera J; Kunz M
Mol Cancer; 2009 Jul; 8():53. PubMed ID: 19642975
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer.
Radhakrishnan VM; Jensen TJ; Cui H; Futscher BW; Martinez JD
Genes Chromosomes Cancer; 2011 Oct; 50(10):830-6. PubMed ID: 21755566
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma.
Chan SY; To KF; Leung SF; Yip WW; Mak MK; Chung GT; Lo KW
Oncol Rep; 2010 Oct; 24(4):949-55. PubMed ID: 20811675
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.
Yang H; Zhao R; Lee MH
Mol Cancer Ther; 2006 Feb; 5(2):253-60. PubMed ID: 16505098
[TBL] [Abstract][Full Text] [Related]
8. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
9. Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation.
Lal G; Padmanabha L; Provenzano M; Fitzgerald M; Weydert J; Domann FE
Cancer Lett; 2008 Aug; 267(1):165-74. PubMed ID: 18440129
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of the cell type-specific gene 14-3-3sigma.
Oshiro MM; Futscher BW; Lisberg A; Wozniak RJ; Klimecki WT; Domann FE; Cress AE
Neoplasia; 2005 Sep; 7(9):799-808. PubMed ID: 16229802
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis.
Luo J; Feng J; Lu J; Wang Y; Tang X; Xie F; Li W
Med Oncol; 2010 Sep; 27(3):791-7. PubMed ID: 19685192
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M; Calvano JE; Ho GH; Orlow I; Cordón-Cardó C; Borgen PI; Van Zee KJ
Cancer Genet Cytogenet; 2001 Mar; 125(2):131-8. PubMed ID: 11369056
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers.
Suzuki H; Itoh F; Toyota M; Kikuchi T; Kakiuchi H; Imai K
Cancer Res; 2000 Aug; 60(16):4353-7. PubMed ID: 10969776
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.
Akahira J; Sugihashi Y; Suzuki T; Ito K; Niikura H; Moriya T; Nitta M; Okamura H; Inoue S; Sasano H; Okamura K; Yaegashi N
Clin Cancer Res; 2004 Apr; 10(8):2687-93. PubMed ID: 15102672
[TBL] [Abstract][Full Text] [Related]
16. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3sigma negatively regulates the cell cycle, and its down-regulation is associated with poor outcome in intrahepatic cholangiocarcinoma.
Kuroda Y; Aishima S; Taketomi A; Nishihara Y; Iguchi T; Taguchi K; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Jul; 38(7):1014-1022. PubMed ID: 17391729
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
19. Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome.
Yoon NK; Seligson DB; Chia D; Elshimali Y; Sulur G; Li A; Horvath S; Maresh E; Mah V; Bose S; Bonavida B; Goodglick L
Cancer Biomark; 2009; 5(4):215-24. PubMed ID: 19729831
[TBL] [Abstract][Full Text] [Related]
20. Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome.
Holm R; Ali T; Svendsrud DH; Nesland JM; Kristensen GB; Lyng H
Oncol Rep; 2009 Jul; 22(1):11-5. PubMed ID: 19513498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
